Triple agonist hub
Retatrutide: GLP-1/GIP/glucagon research hub
Central page for Retatrutide variants with reconstitution resources, related incretin links and educational context for triple agonist research.
Triple agonist context
Retatrutide is studied for simultaneous GLP-1, GIP and glucagon pathway targeting. This hub organises research-format variants.
GLP-1 cluster linking
The page connects Retatrutide with Semaglutide, Tirzepatide and Cagrilintide so the topic cluster is clear for readers and search engines.
Research-only use
The information is educational and does not provide administration or treatment instructions.
Available protocol variants
Choose the exact guide you want to view.
Retatrutide
Retatrutide is a novel triple agonist targeting the gut hormone, GIP and glucagon receptors, studied for significant weight loss and metabolic improvement in obesity and type 2 diabetes. Research sources report subcutaneous administration of 2 mg to 12 mg, once weekly, increased gradually.
View protocolRetatrutide
Retatrutide is an investigational triple agonist peptide (targeting gut hormone, GIP and glucagon receptors) in development for obesity and T2DM. Phase 2 trials showed up to 24% body weight change at 48 weeks, while new Phase 3 data (TRIUMPH-4, 2026) reported 28.7% weight change at 68 weeks—the highest reported performance in a Phase 3 obesity trial. Research sources report subcutaneous administration of 2 mg to 12 mg, once weekly, increased gradually.
View protocolRetatrutide
Retatrutide is a triple gut hormone receptor, GIP and glucagon agonist. Research sources report subcutaneous administration of 2 mg to 12 mg, once weekly, increased gradually.
View protocolRetatrutide
Retatrutide is a triple gut hormone receptor, GIP and glucagon agonist. Research sources report subcutaneous administration of 2 mg to 12 mg, once weekly, increased gradually.
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
Common questions
Short research-only answers for this topic cluster.
What is Retatrutide?
Retatrutide is studied as a triple agonist targeting GIP, GLP-1 and glucagon receptors.
Why is it linked with GLP-1 content?
It belongs in the incretin and metabolic research cluster alongside Semaglutide and Tirzepatide.
Does the page provide use instructions?
No. The content is educational and research-only.
References
- New England Journal of Medicine (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2, 48 weeks
View Source - JAMA Network (2023) — Retatrutide Phase 2: 24% weight loss at 12 mg weekly
View Source - The Lancet (2023) — Retatrutide in T2D: Phase 2 (weight loss and glycemic outcomes)
View Source - Katsi V et al. Biomolecules 2025 — Retatrutide-A Game Changer in Obesity Pharmacotherapy.
View Source - Abdrabou Abouelmagd A et al. Proc (Bayl Univ Med Cent) 2025 — Efficacy and safety of retatrutide in obesity: systematic review and meta-analysis.
View Source - Nature Reviews Endocrinology (2024) — Triple agonists for obesity and diabetes: clinical overview
View Source - The Lancet (2023) — Retatrutide in T2DM — Phase 2 (36 wks, HbA1c reductions, weight change)
View Source - NEJM (2023) — Triple agonist Retatrutide for obesity — Phase 2 (48 wks, up to 24% weight change)
View Source - Cell Metabolism (2022) — LY3437943 (Retatrutide): discovery to clinical proof of concept (gut hormone receptor, GIP and glucagon triple agonist)
View Source - ClinicalTrials.gov — Study of Retatrutide in adults with obesity (NCT04881760)
View Source - Goldney J et al. Curr Cardiovasc Risk Rep 2025 — Triple Agonism Based Therapies for Obesity.
View Source - TRIUMPH-4 Phase 3 (2026) — Retatrutide Phase 3: 28.7% weight change at 68 weeks — highest performance in an obesity trial.
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.